Valuation: Tenax Therapeutics, Inc.

Market Cap 81Cr 71Cr 65Cr 60Cr 113.45Cr 7.8TCr 115.97Cr 780.54Cr 307Cr 3.82TCr 304.12Cr 297.45Cr 13TCr P/E 2026 *
-11.3x
P/E 2027 * -11.5x
Enterprise Value 81Cr 71Cr 65Cr 60Cr 113.45Cr 7.8TCr 115.97Cr 780.54Cr 307Cr 3.82TCr 304.12Cr 297.45Cr 13TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day+5.11%
1 week-9.69%
Current month+8.93%
1 month+32.08%
3 months+9.69%
6 months-1.25%
Current year+30.02%
1 week 14.55
Extreme 14.55
17.22
1 month 11.86
Extreme 11.861
19.4
Current year 10.25
Extreme 10.25
19.4
1 year 5.77
Extreme 5.7719
19.4
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,135.04
10 years 2.77
Extreme 2.77
85,120
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 21/01/2025
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 69 25/02/2021
Date Insider Type Main position Quantity % Market Cap.
13/07/26 Fiscal year

Chief Executive Officer

17,438 0.0657%
11/05/26 Free

Chief Financial Officer

4,60,000 2.6748%
11/05/26 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+5.11%-9.69%+165.94%-36.96% 81Cr
-1.29%-3.11%-0.35%+3.09% 4.92TCr
+3.90%-0.39%+386.06%+593.85% 3.96TCr
-1.70%+4.46%+5.93%+60.25% 3.47TCr
-2.01%-0.76%+28.41%-8.01% 3.44TCr
+0.06%+0.34%+2.38%+34.38% 2.71TCr
+0.46%-3.49% - - 1.62TCr
-0.04%-0.09%+72.42%+115.55% 1.54TCr
+1.12%+1.91%+14.54%+19.16% 1.41TCr
0.00%+1.36%+18.43%-30.79% 1.3TCr
Average +0.56%-0.95%+77.08%+83.39% 2.44TCr
Weighted average by Cap. -0.04%-0.21%+79.75%+122.75%

Financials

2026 *2027 *
Net sales - -
Net income -7.97Cr -6.97Cr -6.43Cr -5.92Cr -11Cr -767.6Cr -11Cr -77Cr -30Cr -375.94Cr -30Cr -29Cr -1.29TCr -9.4Cr -8.21Cr -7.58Cr -6.98Cr -13Cr -904.91Cr -13Cr -91Cr -36Cr -443.19Cr -35Cr -35Cr -1.53TCr
Net Debt - -
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
17/26/17 $15.85 +5.11% 8,08,315
16/26/16 $15.08 -1.69% 9,25,811
15/26/15 $15.34 -1.41% 9,79,815
14/26/14 $15.56 -2.63% 12,72,470
13/26/13 $15.98 -8.95% 12,99,236
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.85USD
Average target price
34.75USD
Spread / Average Target
+119.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock